Corsair Pharma demonstrated sustained, stable delivery of treprostinil via a 24-hour transdermal patch in first-in-human trials, maintaining consistent plasma levels with minimal fluctuation. This approach addresses a significant limitation of current pulmonary hypertension therapies—the need for frequent dosing or continuous infusion—by enabling once-daily administration with pharmacokinetic stability comparable to subcutaneous delivery.
Key Points
- 24-hour patch maintains steady treprostinil levels with minimal peak-to-trough variation
- Transdermal delivery matches subcutaneous pharmacokinetics without continuous infusion burden
- Dose-proportional patch sizes simplify patient titration and individualization
Longevity Analysis
Pulmonary hypertension accelerates cardiovascular decline and reduces life expectancy, partly through the physiologic burden imposed by current treatment regimens. Continuous infusion therapies disrupt circadian rhythms, impose social constraints, and create opportunities for medication errors—all factors that compromise long-term adherence and cardiovascular stability. A transdermal patch that maintains stable drug exposure over 24 hours addresses these practical obstacles to sustained treatment consistency. For aging populations managing chronic vascular disease, reducing treatment complexity while preserving pharmacologic precision becomes increasingly important to outcomes. This mechanism also aligns with how the body naturally regulates vascular tone—through continuous, balanced signaling rather than the peaks and troughs of bolus dosing.
Original published by LT Wire.